Evidence map›Paper›PMID 26819879›Full record

ArticleMass spectrometry (Tokyo, Japan)2014

Solving CASMI 2013 with MetFrag, MetFusion and MOLGEN-MS/MS.

Emma L Schymanski, Michael Gerlich, Christoph Ruttkies, Steffen Neumann

Abstract read
In one paragraph

Article in Mass spectrometry (Tokyo, Japan), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. The DNA adenine methylase ofFrontiers in microbiology · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Winners of CASMI2013: Automated Tools and Challenge Data.Mass spectrometry (Tokyo, Japan) · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emma L SchymanskiEawag: Swiss Federal Institute of Aquatic Science and Technology.
Michael GerlichLeibniz Institute of Plant Biochemistry, Department of Stress and Developmental Biology.
Christoph RuttkiesLeibniz Institute of Plant Biochemistry, Department of Stress and Developmental Biology.
Steffen NeumannLeibniz Institute of Plant Biochemistry, Department of Stress and Developmental Biology.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The second Critical Assessment of Small Molecule Identification (CASMI) contest took place in 2013. A joint team from the Swiss Federal Institute of Aquatic Science and Technology (Eawag) and Leibniz Institute of Plant Biochemistry (IPB) participated in CASMI 2013 with an automatic workflow-style entry. MOLGEN-MS/MS was used for Category 1, molecular formula calculation, restricted by the information given for each challenge. MetFrag and MetFusion were used for Category 2, structure identification, retrieving candidates from the compound databases KEGG, PubChem and ChemSpider and joining these lists pre-submission. The results from Category 1 were used to guide whether formula or exact mass searches were performed for Category 2. The Category 2 results were impressive considering the database size and automated regime used, although these could not compete with the manual approach of the contest winner. The Category 1 results were affected by large m/z and ppm values in the challenge data, where strategies beyond pure enumeration from other participants were more successful. However, the combination used for the CASMI 2013 entries was extremely useful for developing decision-making criteria for automatic, high throughput general unknown (non-target) identification and for future contests.

Indexed as

chemical clusteringcomputational mass spectrometrymaximum common substructuresmall molecule identification

Identifiers

PMID26819879
PMCPMC4321341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.